IR-News

AUSSENDER



Medigene AG
Ansprechpartner: Medigene PR/IR
Tel.: +49 89 2000 33 3301
E-Mail: investor@medigene.com

WEITERE IR-NEWS

pta20190222009
Business news for the stock market

Medigene AG: Medigene participates at upcoming conferences


Planegg (pta009/22.02.2019/07:30) - Medigene AG (FSE: MDG1, Prime Standard, SDAX) today announced its participation at the following upcoming scientific conferences:

ACUTE LEUKEMIAS XVII
Date: 24 - 27 February
Location: Munich, Germany

Whistler Conference Centre
Date: 10 - 14 March 2019
Location: Whistler, Canada

Immuno Oncology Summit Europe
Date: 18 - 22 March 2019
Location: London, UK
Dr Slavoljub Milosevic will give a presentation on "Rapid High-Throughput Functional Selection of Neoantigens and Assessment of Their Safety" on 18 March 2019

9th Gene Quantification Event qPCR dPCR & NGS 2019
Symposium & Industrial Exhibition & Application Workshops
Date: 18 - 22 March 2019
Location: Freising-Weihenstephan, Germany

International Cellular Therapy Symposium 2019
Date: 22 - 23 March 2019
Location: Erlangen, Germany
Dr. Daniel Sommermeyer will give a poster presentation on "HA-1-specific T-cell receptors for the treatment of hematological malignancies" on 22 March 2019

Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard, SDAX) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in pre-clinical and clinical development.

For more information, please visit http://www.medigene.com

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.

Contact Medigene AG
Julia Hofmann, Dr. Robert Mayer
Tel.: +49 - 89 - 20 00 33 - 33 01,
email: investor@medigene.com

In case you no longer wish to receive any information about Medigene, please inform us by e-mail (investor@medigene.com). We will then delete your address from our distribution list.

(end)
emitter: Medigene AG
Lochhamer Straße 11
82152 Planegg
Germany
contact person: Medigene PR/IR
phone: +49 89 2000 33 3301
e-mail: investor@medigene.com
website: www.medigene.de
stock exchanges: regulated market in Frankfurt; free market in Dusseldorf, free market in Hamburg, free market in Hannover, free market in Munich, free market in Stuttgart; open market in Berlin, Tradegate
ISIN(s): DE000A1X3W00 (share)
|
|
98.243 Abonnenten
|
176.376 Meldungen
|
71.658 Pressefotos

BUSINESS

12.12.2019 - 13:45 | ISM International School of Management
12.12.2019 - 12:30 | pressetext.redaktion
12.12.2019 - 09:46 | danberg&danberg.
12.12.2019 - 09:40 | VBV-Gruppe
12.12.2019 - 06:10 | pressetext.redaktion
Top